Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Breast Cancer Drug Shrinks Tumors or Slows Growth in Up to Half of Women

07.06.2004


A new and experimental breast cancer drug called lapatinib inhibited tumor growth in nearly half of women who took it for eight weeks in a national Phase I clinical trial, according to results of a study being presented at the annual American Society of Clinical Oncology meeting in New Orleans.


Kimberly Blackwell, M.D., assistant professor of medicine, Duke University Medical Center
CREDIT: Duke University Medical Center



Kimberly Blackwell, M.D., an oncologist from the Duke Comprehensive Cancer Center, presented data showing that 46 percent of breast cancer patients who took the oral drug for eight weeks had stable disease or tumor shrinkage. Approximately 24 percent of patients who took the drug for four months had stable disease or tumor shrinkage.

The results are quite encouraging, said Blackwell, because lapatinib is one of the first drugs to elicit a response in women whose tumors did not respond to at least two traditional therapies, including trastuzumab (Herceptin).


Trastuzumab is the front-line drug used to treat women whose tumors overproduce a growth-regulating protein called Her-2. Trastuzumab blocks the Her-2 receptor on cancer cells and inhibits its signaling, thereby shrinking or stabilizing the tumor.

But nearly one-third of tumors with Her-2 over-expression do not respond to trastuzumab, said Blackwell. In the current trial, the majority of patients -- 59 percent -- had progressed through three, four or five traditional cancer drugs.

Lapatinib represents a new type of therapy because it targets Her-2 plus another growth factor protein called Epidermal Growth Factor (EGFR). "Blocking the action of two growth factors has a more profound effect on inhibiting cell growth than blocking a single growth factor, and we think this dual action on breast cancer cells is responsible for the positive effects we’re seeing," said Blackwell. The study was funded by GlaxoSmithKline, the maker of lapatinib.

The study showed that lapatinib was safe and had minimal side effects, because it targets only these two very specific receptor sites on breast cancer cells, said Blackwell. Five percent of women experienced a rash, 5 percent had fatigue, and 10 percent had diarrhea. In contrast, chemotherapy can cause debilitating nausea, anemia, fatigue and the potential for heart and liver damage.

The trial is continuing to recruit patients at Duke and other sites around the country.

Becky Levine | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=7649

More articles from Health and Medicine:

nachricht Cystic fibrosis alters the structure of mucus in airways
28.06.2017 | University of Iowa Health Care

nachricht Mice provide insight into genetics of autism spectrum disorders
28.06.2017 | University of California - Davis

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Supersensitive through quantum entanglement

28.06.2017 | Physics and Astronomy

X-ray photoelectron spectroscopy under real ambient pressure conditions

28.06.2017 | Physics and Astronomy

Mice provide insight into genetics of autism spectrum disorders

28.06.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>